IL-34 Antibody Inhibits CSF-1R Binding to Reduce Cancer Treatment Resistance

Solution Overview

Problem

Treatment-resistant cancers pose a significant challenge due to their resistance to chemotherapy and radiation therapy, leading to increased side effects and reduced efficacy, with existing treatments struggling to distinguish between cancer and normal tissues effectively.

Innovation Solution

A substance specifically inhibiting the binding between interleukin-34 (IL-34) and colony stimulating factor-1 receptor (CSF-1R) using an IL-34-specific antibody is used to reduce treatment resistance, particularly in combination with chemotherapy, radiation therapy, and immunotherapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy or radiation therapy is administered to treat cancer, then cancer treatment is achieved, but treatment-resistant cancers emerge and side effects increase

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an antibody as an intermediary substance that specifically binds to IL-34, preventing it from activating CSF-1R on macrophages. This intermediary blocks the immunosuppressive signaling pathway without directly affecting the cancer cells or the chemotherapy/radiation therapy, thereby enhancing treatment efficacy while reducing the emergence of treatment resistance and minimizing side effects on normal tissues.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If larger amounts of anticancer agents or higher intensity radiation are administered to overcome treatment resistance, then cancer treatment effectiveness may improve, but side effects become intolerable and normal tissue exposure increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by administering the anti-IL-34 antibody before or concurrent with chemotherapy or radiation therapy. This preliminary intervention blocks the IL-34/CSF-1R immunosuppressive pathway in advance, preventing cancer cells from developing resistance during treatment and reducing the need to increase drug doses or radiation intensity, thereby avoiding intolerable side effects and excessive normal tissue exposure.

Inventive Principle:
Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of this substance effectively reduces treatment resistance in cancer cells, enhancing the efficacy of cancer treatments and minimizing side effects by inhibiting the immunosuppressive action of IL-34, thereby promoting sensitivity to anticancer agents and radiation.

Implementation Method 1

a substance specifically inhibiting the binding between interleukin-34 (IL-34) and colony stimulating factor-1 receptor (CSF-1R) using an IL-34-specific antibody

Methodology Applied
Scientific EffectAntibody-antigen binding:

Data Source

PatentEP3311840B1Treatment-resistance reducing agent for treatment-resistant cancer
Publication Date: 2021.09.29
  • EP3311840B1 patent drawingFigure 1~2
  • EP3311840B1 patent drawingFigure 3~5
  • EP3311840B1 patent drawingFigure 6

AI summary

[Problem] To provide a treatment-resistance reducing agent for treatment-resistant cancer, said treatment-resistance reducing agent being capable of eliminating or reducing treatment-resistance, in particular, drug-resistance of cancer and thus enhancing the efficacy of cancer treatment. [Solution] A treatment-resistance reducing agent for treatment-resistant cancer that contains, as active ingredient(s), a substance specifically inhibiting the binding of interleukin-34 to colony stimulating factor-1 receptor and/or a substance suppressing the expression of interleukin-34 in a cancer cell. According to the present invention, the treatment resistance of cancer, which is resistant to a treatment method such as the administration of an anticancer agent or radiation therapy, can be reduced and, therefore, the efficacy of cancer treatment can be enhanced and the occurrence risk of a side effect can be suppressed.